Prescribing information. Santa Monica, CA: Kite Pharma, Inc.; May 2019.
Available at www.yescarta.com. Accessed October 31, 2019.
Data on File. Kite Pharma - Yescarta: Primary Results of the Pivotal ZUMA-1
Phase 2 Study. MRC-00038. October 2017.
National Comprehensive Cancer Network. B-cell Lymphomas Version 5.2019.
Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
Accessed October 31, 2019.
National Comprehensive Cancer Network Drug and Biologics Compendium. Available
at http://www.nccn.org/professionals/drug_compendium. Accessed October 31, 2019.
National Comprehensive Cancer Network. Central Nervous System Cancers Version
3.2019. Available at:
https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed October
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell
Therapy in Refractory Large B-Cell Lymphoma. NEJM 2017; 377: 2531-44.
Bennani NN, Maurer MJ, Nastoupil LJ, et al. Experience with Axicabtagene
Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from
the US Lymphoma CAR T Consortium. Blood (2019); 134 (Supplement_1): 763.